Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab versus placebo in idiopathic pulmonary fibrosis
2022-502954-15-00Phase 2Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Axatilimab with Placebo (2 arms). Primary endpoint: Annualized rate of decline in morning pre-dose trough forced vital capacity. Started Jun 2024; status: completed.
02
Drugs
axatilimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2022-502954-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502954-15-00.